Kit for judging therapeutic response of NSCLC (non-small-cell lung cancer) patient to gefitinib

Abstract

The invention discloses a kit for judging therapeutic response of an NSCLC (non-small-cell lung cancer) patient to gefitinib. The kit comprises a reagent capable of being used for detecting the genotypes of an rs9912773 site and / or an rs1294991 site in an STAT3 gene. According to the kit, correlation analysis of therapeutic response of an SNP (single nucleotide polymorphism) site of the STAT3 gene and the gefitinib to the advanced NSCLC through genetic typing of the patient discovers that the therapeutic response of the NSCLC patient to the gefitinib can be judged according to the genotypes of the rs9912773 site and / or the rs1294991 site. The development of the kit provides a reliable and sensitive way for determining a therapy scheme of the advanced NSCLC patient.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to a kit for judging the responsiveness of advanced non-small cell lung cancer (NSCLC) patients to gefitinib treatment and the application of SNP in preparing the kit. Background technique [0002] Lung cancer is one of the most common malignant tumors with the highest mortality rate, and its morbidity and mortality are still increasing year by year. Among them, non-small cell lung cancer (NSCLC) accounts for more than 80% of the whole lung cancer, and most of the patients are already in advanced stage when they are diagnosed. Chemotherapy used to be the most important treatment for advanced non-small cell lung cancer, but even with the best chemotherapy regimen, the total effective rate of current treatment is less than 50%, and the 1-year survival rate is only about 40%. [0003] The emergence of targeted therapy drugs has changed the current treatment status of non-small cell lung cance...

AI Technical Summary

Problems solved by technology

Chemotherapy used to be the most important treatment for advanced non-small cell lung cancer, but even with the best chemotherapy regimen, the total effective rate of current treatment is less than 50%, and the 1-year survival rate is only about 40%

However, EGFR gene mutation, as a biomarker for predicting the efficacy of gefitinib, has certain shortcomings: ①The detection of mutation requires tumor tissue, and most lung cancers are already in the advanced stage when they are first diagnosed, and they lose the opportunity to obtain tumor samples through surgery. It is possible for a small number of patients to obtain biopsy specimens, and it is also difficult to perform mutation detection due to the limited detection rate and the limited amount of biopsy specimens. Currently, the proportion of patients who can meet the requirements of mutation detection clinically is less than 20% (about 17% in ISEL research). %); ②Gene mutations are affected by tumor heterogeneity. Tumor samples obtained from the same patient at different sites or at different stages of the disease may have different mutation detection results, so the detected results may not represent the characteristics of the whole body and the whole tumor ; ③The process of mutation detection is complicated, the requirements for instruments and equipment are high, it is difficult for general laboratories to carry out, and the detection cost is also high, which affects its wide clinical application

Images